ClinicalTrials.gg
RecruitingNCT07853781Updated Nov 20, 2026

First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE4D Imaging in Healthy Volunteers

A Phase 1 interventional study of [11C]JMJ-129-d2 in Healthy, sponsored by National Institute of Mental Health (NIMH). Recruiting at 1 site in United States. Open to participants aged 18 Years to 105 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by National Institute of Mental Health (NIMH) · Phase 1, Interventional, and Diagnostic

How we know

Updated Nov 20, 2026Start date movedTitle changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 105 Years
Sex
All
01

Study summary

Background:

PDE4D is a protein found in the brain. It helps control chemical signals that affect mood, memory, and thinking. Problems with PDE4D may play a role in depression and Alzheimer's disease. Being able to measure PDE4D levels in the body would help doctors identify and manage these diseases. Researchers want to find out if a new tracer (a radioactive substance injected during imaging scans) can help them see PDE4D in people more effectively.

Objective:

To test a new tracer ([11C]JMJ-129-d2) during imaging scans of the brain and body in healthy people.

Eligibility:

Healthy people aged 18 years and older. They must have been screened under protocols 01M0254 or 17M0181.

Design:

All participants will give samples of blood and urine. They will have a test of their heart function. A plastic tube will be inserted into a vein in their arm; the new tracer will be given through this tube.

Some participants will have 1 positron emission tomography (PET)/computed tomography (CT) scan of their whole body. They will lie on a padded bed that slides into a doughnut-shaped machine; the machine uses x-rays to create images of the inside of the body.

Some participants will have 1 or 2 PET/CT scans of their brain only. Their head will be supported to keep it still during the scan. They will also have a magnetic resonance imaging (MRI) scan of the brain. MRI uses magnetic fields to capture images of the inside of the body. The MRI scan may require a second visit.

All participants will receive a follow-up call to check on their well-being 1 to 3 business days after their scans....

Read the detailed description

Study Description:

This is a Phase 1, first-in-human, single-site, open-label, sequential cohort study designed to evaluate the safety, biodistribution, metabolic stability, and quantitative brain imaging characteristics of the novel positron emission tomography (PET) radioligand [11C]JMJ-129-d2 in healthy volunteers. The study will proceed through staged cohorts including whole-body dosimetry, evaluation of brain imaging performance, and test-retest reproducibility. We hypothesize that [11C]JMJ-129-d2 will demonstrate acceptable safety, radiation dosimetry typical of 11C-labeled radioligands, and stable quantitative brain PET measures suitable for reproducible in vivo imaging of Phosphodiesterase 4D (PDE4D).

Objectives:

Primary Objective:

To evaluate the safety and quantitative brain imaging properties of [11C]JMJ-129-d2 in healthy volunteers.

Secondary Objectives:

  • To estimate whole-body biodistribution and radiation dosimetry.
  • To evaluate stability and reliability of regional total distribution volume (VT) in brain.
  • To evaluate test-retest reproducibility of brain VT.

Endpoints:

Primary Endpoint:

Regional VT derived from kinetic modeling of dynamic brain PET data using a metabolite-corrected arterial input function.

Secondary Endpoints:

  • Organ residence times and estimated effective radiation dose (rem).
  • Regional VT time-stability metric in brain.
  • Test-retest variability (TRV) and intraclass correlation coefficient (ICC) of regional VT in brain.
02

Conditions studied

  • Healthy

Keywords

  • Kinetic Modeling
  • Dosimetry
  • Whole-body imaging
  • Brain Imaging
  • Phosphodiesterase 4D (PDE4D)
  • Positron Emission Tomography (PET)/CT Imaging
  • 11C-JMJ-129-d2
03

In context

Lead sponsor

National Institute of Mental Health (NIMH) is the lead sponsor of 367 studies on the registry; 45 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 24 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 105 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Provision of signed and dated under this protocol.
  • Successful completion of screening under protocol 01M0254 or 17M0181 and confirmation of eligibility.
  • Age 18 years or older.
  • In good general health as determined by medical history, physical examination, vital signs, laboratory testing, and .
  • Willingness and ability to comply with all study procedures.
  • Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.
  • Agree to adhere to the lifestyle considerations

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).
  • Any current persistent psychiatric disorder, including but not limited to: schizophrenia spectrum and other psychotic disorders; bipolar and related disorders; and depressive disorders.
  • History of neurologic illness or injury with the potential to affect study data interpretation.
  • History of seizures, other than in childhood and related to fever.
  • Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits.
  • Inability to lie flat on camera bed for at least two hours, including claustrophobia and weight greater than the maximum for the scanner (500 lbs).
  • Infection.
  • Pregnancy or breast feeding.
  • Participants must not have substance use disorder or alcohol use disorder.
  • Unable to travel to the NIH.
  • Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye.
  • Known to phosphodiesterase-4 (PDE-4) inhibitors (e.g. apremilast, roflumilast, crisaborole).
  • Current use of any PDE4 inhibitor (e.g., apremilast, roflumilast, crisaborole), or use within 7 days prior to PET imaging.
  • Taking inhibitors (e.g. grapefruit juice, clarithromycin, erythromycin, ritonavir); CYP3A4 inducers (e.g. phenobarbital St. John's Wort, rifampicin) or oral containing gestodene and ethinyl estradiol, which may alter the metabolism and affect the kinetics of the study drug.

EXCLUSION OF CHILDREN

Inclusion of children is not appropriate, because this protocol has more than minimal risk from radiation exposure without the possibility of direct benefit.

EXCLUSION OF PREGNANT OR BREASTFEEDING WOMEN

Pregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will perform a urine pregnancy test at screening and prior to all procedures to ensure participants are not pregnant. The test must be negative in order to continue on the study. In addition to completing a negative urine pregnancy test, on the day of PET scanning prior to PET scan procedures, participants of will undergo a clinical pregnancy screening interview with a licensed independent practitioner to confirm lack of pregnancy.

EXCLUSION OF PARTICIPANTS WHO ARE HIV POSITIVE

Persons with HIV infection are excluded because HIV infection itself may change cAMP signaling.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    One-arm

    All subjects will receive the same tests.

    Drug: [11C]JMJ-129-d2

Interventions

  • Drug[11C]JMJ-129-d2

    Injected IV followed by PET scanning

06

What researchers measure

Primary outcomes

  1. Total Volume of Distribution

    Regional VT from kinetic modeling

    Time frame: 120 minutes

Secondary outcomes

  1. Dosimetry, ICC, aTRV, and biodistribution

    Organ residence times and effective dose (rem); regional VT time-stability; test retest variability (TRV) and intraclass correlation coefficient (ICC) of regional VT.

    Time frame: 120 minutes

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • NIH Clinical Center Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Individual participant data

Plan to share: Yes — The results will be submitted to ClinicalTrials.gov

Supporting information: Study protocol

Time frame: 18 months after closure of protocol.

Access criteria: BTRIS

09

Timeline

25 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Feb 2030, 38 months later.

Start moved 21 times since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, last on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 2, 2026
StartEst.
Nov 25, 2026was Oct 2026
Primary completionEst.
Feb 22, 2030
CompletionEst.
Feb 5, 2031
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 26, 2026→Nov 25, 2026
moved 21 times, Oct 22, 2026 – Nov 20, 2026
Eligibility
Revised
Oct 8, 2026
Title
First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE-4DPDE4D Imaging in Healthy Volunteers
Oct 9, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 25 updates
  1. Nov 20, 2026
    Start date Nov 24, 2026→Nov 25, 2026
  2. Nov 19, 2026
    Start date Nov 23, 2026→Nov 24, 2026
  3. Nov 18, 2026
    Start date Nov 22, 2026→Nov 23, 2026
  4. Nov 17, 2026
    Start date Nov 19, 2026→Nov 22, 2026
  5. Nov 16, 2026
    Start date Nov 18, 2026→Nov 19, 2026
  6. Nov 13, 2026
    Start date Nov 17, 2026→Nov 18, 2026
  7. Nov 12, 2026
    Start date Nov 15, 2026→Nov 17, 2026
  8. Nov 10, 2026
    Start date Nov 12, 2026→Nov 15, 2026
  9. Nov 9, 2026
    Start date Nov 11, 2026→Nov 12, 2026
  10. Nov 6, 2026
    Start date Nov 10, 2026→Nov 11, 2026
  11. Nov 5, 2026
    Start date Nov 9, 2026→Nov 10, 2026
    + 1 other change: description
  12. Nov 4, 2026
    Start date Nov 8, 2026→Nov 9, 2026
  13. Nov 3, 2026
    Start date Nov 5, 2026→Nov 8, 2026
  14. Nov 2, 2026
    Start date Nov 4, 2026→Nov 5, 2026
  15. Oct 30, 2026
    Start date Nov 3, 2026→Nov 4, 2026
  16. Oct 29, 2026
    Start date Nov 2, 2026→Nov 3, 2026
  17. Oct 28, 2026
    Start date Nov 1, 2026→Nov 2, 2026
  18. Oct 27, 2026
    Start date Oct 29, 2026→Nov 1, 2026
  19. Oct 26, 2026
    Start date Oct 28, 2026→Oct 29, 2026
  20. Oct 23, 2026
    Start date Oct 27, 2026→Oct 28, 2026
  21. Oct 22, 2026
    Start date Oct 26, 2026→Oct 27, 2026
  22. Oct 9, 2026
    Title First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE-4DPDE4D Imaging in Healthy Volunteers
    + 2 other changes: verification date and description
  23. Oct 8, 2026
    Eligibility Revised
  24. Oct 5, 2026
    Minor edits only
    + 1 other change: verification date
  25. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853781
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
Feb 22, 2030 (estimated)
Completion
Feb 5, 2031 (estimated)
Last update
Nov 20, 2026

Study contacts

Tara N Turon, C.R.N.P.
Contact
tara.turon@nih.gov
(301) 827-6599
Robert B Innis, M.D.
Contact
robert.innis@nih.gov
(301) 594-1368
Robert B Innis, M.D.
principal investigator · National Institute of Mental Health (NIMH)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion